Войти в систему Зарегистрироваться бесплатно

Inhibrx Доход Q / Q

Что обозначает Доход Q / Q в Inhibrx?

Доход Q / Q Inhibrx, Inc. является 233.33%

Какое определение для Доход Q / Q?

Квартальный рост выручки в годовом исчислении - это увеличение дохода компании по сравнению с показателями соответствующего квартала предыдущего года, выраженными в процентах.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Доход Q / Q компаний в Health Care сектор на NASDAQ по сравнению с Inhibrx

Что делает Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Компании с доход q / q похож на Inhibrx